8.1. intravesical surveillance follow-up. 8.1.1. follow-up low-risk nmibc low-risk group nearly always low stage lg/g1. small, ta lg/g1 papillary recurrence present immediate danger patient early detection essential successful therapy . addition, recurrence 5 recurrence-free years low (le: 3). therefore, low-risk tumours, 5 years follow-up, discontinuation cystoscopy replacement less invasive methods considered . 8.1.2. follow-up intermediate-risk nmibc patients intermediate-risk group carry risk progression somewhere low high risk categories ; therefore, intensity follow-up scheme could adapted line this. based safety reduced intensity follow-up scheme compared high-risk nmibc, small rct multiple and/or recurrent low grade tumours , low-grade intermediate-risk nmibc safely followed-up cystoscopy 3 months and, negative, 6 monthly cystoscopies 2 years followed yearly cystoscopies 10 years. surveillance scheme disease category already adopted scottish access collaborative workstream . due lack data supporting safety reduced scheme subgroup high-grade intermediate-risk nmibc panel recommend group followed-up way high-risk nmibc. 8.1.3. follow-up high- high-risk nmibc tumours originally, high risk, high risk treated conservatively prompt detection muscle-invasive hg/g3 non-muscle-invasive recurrence crucial percentage tumours missed low possible delay diagnosis therapy life-threatening. therefore, best surveillance strategy patients continue include frequent cystoscopy cytology. recurrences ten years tumour-free unusual . therefore, optimal surveillance strategy patients includes initial frequent cystoscopy cytology life-long follow-up . 8.1.4. follow-up extravesical sites urothelium follow-up strategy must reflect risk extravesical recurrence (prostatic urethra men uut genders). risk becomes significant sites high-risk tumours , 10 year tumour rates uut varing 2.8% cis 25% patients multiple recurrent high risk nmibc . urine cytology, cystoscopy ct urography key investigations early detection extravesical recurrence. 8.1.5. aids tumour detection follow-up 8.1.5.1. enhanced visualisation may role newer methods tumour visualisation follow-up cystoscopy. two prospective studies blue light flexible cystoscopy (blfc) surveillance nmibc, blfc allowed identification 4 5.7 % recurrences would missed case wl cystoscopy alone . hand, prospective study nbi nmibc surveillance failed show benefit nbi wl cystoscopy alone . 8.1.5.2. ultrasound patients initially diagnosed ta lg/g1–2 bc, us bladder and/or urinary marker may mode surveillance case cystoscopy possible refused patient . 8.1.5.3. urinary molecular markers urine cytology non-invasive follow-up strategies include urine cytology urinary molecular marker tests adjunct (or companion) tests improve detection time flexible cystoscopy replacement tests reduce number flexible cystoscopies. research carried usefulness urinary cytology vs. urinary molecular markers follow-up nmibc . order reduce replace cystoscopy altogether, urinary markers able detect recurrence risk groups. however, reported low sensitivity lg recurrences limits utility group although recent studies shown reasonable sensitivity low grade recurrences sensitivity 40–65% . according current knowledge, urinary marker replace cystoscopy follow-up lower cystoscopy frequency routine fashion. nonetheless, urinary markers shown fairly high sensitivities detect tumour recurrence, particularly hg disease, along high npvs make premises future implementation follow-up [117,437-439] (table 8.1). table 8.1: urinary markers surveillance setting* markersensitivity overallhgspecificity overallhgppv overallhgnpv overallhgn studies/patientsxpert bc® monitor0.720.880.760.750.430.180.920.9910/> 2000epichecktm0.740.910.840.810.480.430.940.985/1600adx bladdertm0.570.710.620.760.290.370.820.933/1600cx bladder0.91-0.61-0.16-0.98-2/1000fdfgr3+tert0.93-0.79-0.67-0.96-2/250 *data extracted pooled analyses systematic review .hg = high grade; nmibc = non-muscle-invasive bladder cancer; ppv = positive predictive value;npv = negative predictive value; n = number. table 8.2: proposed follow-up schedule based patient’s risk category risk groupcytology*cystoscopyimagingduration follow-uplownoat 3 12 monthsthen annuallynot systematic5 yearsintermediate (not including hg/g3 subgroup)*noat 3 monthsthen every 6 months 2 yearsthen annuallynot systematic10 yearshigh andvery highyes**every 3 months 2 yearsthen every 6 months 5 yearsthen annuallyct annually 5 yearsthen ct every 2 years 10 yearslife long *intermediate-risk hg/g3 subgroup followed-up high-risk** intervals cystoscopy